Skip to main content
RAPP
NASDAQ Life Sciences

Rapport Therapeutics Q2 2026: $56.6M Net Loss, $436.1M Cash Runway into H2 2029, and RAP-219 Phase 3 Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$40.51
Mkt Cap
$2.018B
52W Low
$13.62
52W High
$44.28
52W Position info
197% above low
Off High info
8.5% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RAPP has more than doubled off its 52-week low of $13.62.

Summary

Rapport Therapeutics posted a $56.6M net loss for Q2 2026 and held $436.1M in cash, funding operations into H2 2029. Phase 3 trials for RAP-219 in focal onset seizures have begun, and Phase 2 bipolar mania data are expected in October 2026.


Key Events · Earnings and Guidance · RAPP

  • Q2 2026 Net Loss Widens

    The net loss reached $56.6 million, up from $26.7 million in Q2 2025, as R&D expenses climbed $28.7 million to $51.4 million to support advancing clinical programs.

  • Cash Runway Extended to H2 2029

    With $436.1 million in cash, cash equivalents, and short-term investments at the end of Q2 2026, operations are funded into the second half of 2029.

  • RAP-219 Phase 3 Program Initiated

    Patient enrollment has begun in the FOCUS 1 and FOCUS 2 pivotal trials for focal onset seizures, following China NMPA IND approval, with recruitment expected to start in Q4 2026.

  • Bipolar Mania Phase 2 Data in October 2026

    Topline results from the Phase 2 trial of RAP-219 in bipolar mania are anticipated in October 2026; the trial has been modified to potentially serve as confirmatory evidence of effectiveness.


Analysis · RAPP · Life Sciences

Rapport Therapeutics' Q2 2026 update pairs financials with a pipeline leap that meaningfully advances the RAP-219 program. Enrollment is underway in the Phase 3 FOCUS 1 and FOCUS 2 trials for focal onset seizures, while the Phase 2 bipolar mania study remains on track for topline data in October 2026 — a near-term catalyst. A cash position of $436.1 million extends the runway into the second half of 2029, easing near-term financing concerns. The net loss widened to $56.6 million from $26.7 million a year ago, reflecting higher R&D spending as the pipeline progresses. For a clinical-stage biotech, the combination of pivotal trial initiation, a clear catalyst timeline, and a fortified balance sheet makes this a notable update.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RAPP was trading at $40.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.62 to $44.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RAPP - Latest Insights

RAPP
Nov 04, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.48
Real-time Price: $26.25 info
Change: +$0.7749 (+3%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 7:32 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $26.25 info
Change: +$1.69 (+7%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.56
Real-time Price: $26.25 info
Change: +$0.6978 (+3%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 7:04 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.55
Real-time Price: $26.25 info
Change: +$3.70 (+16%) info
Market Cap: $1.55B info
RAPP
Oct 28, 2026, 6:18 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $21.80
Real-time Price: $26.25 info
Change: +$4.45 (+20%) info
Market Cap: $1.55B info